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Background: Vitamin E is an antioxi-
dant that inhibits mutagenesis and cell
transformation. Previous findings in
five prospective epidemiologic studies
suggested that the level of serum oc-
tocopherol, the predominant form of
vitamin E in the blood, was lower in
subjects who subsequently developed
colorectal cancer than in control sub-
jects. However, the difference was
neither obvious nor statistically sig-
nificant in any one of these five studies.
Purpose: To evaluate in greater detail
the association between serum a-to-
copherol concentration and risk of
colorectal cancer, we pooled and
analyzed the original data from the five
studies. Our analyses were designed to
(a) test the hypothesis with greater
statistical power, (b) examine the as-
sociation after adjustment for serum
cholesterol levels, and (c) evaluate the
association after uniform exclusion of
cases diagnosed shortly after blood
specimens were drawn. Methods: Data
for individual subjects were analyzed.
To make the design of the component
investigations uniformly nested case-
control studies with individual match-
ing, we matched controls to cases in
two of the cohorts. Subjects were
categorized according to study-specific
quartile of serum a-tocopherol level
within the study. The pooled analysis
included 289 cases of colorectal cancer
and 1267 matched controls. Results:
For cancers of the colon and rectum
combined, the matched odds ratio
(OR) for the highest quartile of serum
a-tocopherol concentration compared
with the lowest was 0.6 (95% con-
fidence interval [CI] = 0.4-1.0). Adjust-
ment for serum cholesterol level
attenuated the OR to 0.7 (95% CI =
0.4-1.1). Conclusion: The results sug-
gest that serum a-tocopherol concen-
tration may be inversely related to risk
of colorectal cancer. It is unclear
whether an association exists, however,
because the association between serum
a-tocopherol level and decreased risk
of colorectal cancer was modest, the
CIs were wide, and, overall, the tests
for trend in effect were not significant.
Implications: Larger observational studies
with concurrent dietary data are needed
to determine whether vitamin E has a
modest but potentially important
protective effect against colorectal can-
cer. [J Natl Cancer Inst 84:430-435,
1992]
Vitamin E inhibits mutagenesis and
cell transformation, probably by blocking
peroxidation of lipids in membranes (/).
In some animal models, vitamin E is anti-
carcinogenic, but the study results are not
entirely consistent (1*2).
Although few epidemiologic studies
have examined vitamin E intake in rela-
tion to risk of cancer (3), serum a-to-
copherol concentration, which reflects in-
take of vitamin E, has been examined in
relation to risk of cancer in several
prospective studies (4-10). In reviewing
these studies, we noted results suggesting
that the level of serum a-tocopherol was
lower in subjects who subsequently de-
veloped colorectal cancer, compared with
that in control subjects. However, the dif-
ference in a-tocopherol level was neither
obvious nor statistically significant in any
one of the studies. While the prospective
design in these observational studies was
methodologically strong, the statistical
power in any given study was somewhat
limited. Further, the interpretation of the
findings in some investigations was un-
clear because the inverse association
might have been due to confounding by
serum cholesterol level, which is corre-
lated with serum a-tocopherol, or to an
effect of preclinical disease on the con-
centration of a-tocopherol in the blood.
To evaluate the association between
serum a-tocopherol concentration and
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risk of colorectal cancer in greater detail,
we pooled and analyzed the original data
from the five prospective, nested case-
control studies of this relationship.
Analysis of the combined data allowed us
to (a) test the hypothesis with greater
statistical power, (b) examine the associa-
tion after adjustment for serum choles-
terol levels, and (c) evaluate the associa-
tion after uniform exclusion of cases
diagnosed shortly after blood specimens
were drawn.
Subjects and Methods
By 1988, authors of five prospective
studies had presented data on serum oc-
tocopherol concentration in relation to
risk of colorectal cancer (5-9); no new
studies of this type have been published
since.
In the two other prospective studies of
serum a-tocopherol level in relation to
subsequent cancer, the colorectal cancer
cases were grouped either with all other
cancers (4) or with other gastrointestinal
cancers (10). We estimated that there
were fewer than 10 cases of colorectal
cancer in each of these studies and ex-
cluded them because little additional in-
formation would have been obtained. In
these two studies, serum oc-tocopherol
levels for cases were slightly lower than
those for controls.
Table 1 describes the five original
studies included in the analysis. The fol-
low-up of subjects was virtually complete
in four studies, but the completeness of
follow-up was not determined in one
study (7). Incident cases of colorectal
cancer were used as the end point in all
but one of the studies (8), in which death
from colorectal cancer was the end point.
In addition, the duration and temperature
for storage of blood specimens varied
considerably from study to study.
For the present analysis, the authors of
the five studies provided data on serum
oc-tocopherol and cholesterol concentra-
tion, cigarette smoking, the date the blood
was drawn, and the date of diagnosis for
each subject in the original reports.
The method of selecting controls
varied among studies. In three of the
studies (5,7,9), controls had been individ-
ually matched to cases and the matched
data were supplied for the current
analysis. In the study by Nomura et al.
Table 1. Description of the five prospective studies of serum a-tocopherol concentration
in relation to risk of colorectal cancer that were included in the pooled analysis
Description
Place
Year begun*
No. of subjects
Age,y
Follow-up period, y*,t
Gender
Matching criteria^
Blood specimen storage
No. of yearst
Temperature, °C
Knekt (5)
Finland
1968
36 265
15-99
8
Male and
female
Age, sex,
place of
residence§
14
-20
First author (ref. No.)
Nomura (6)
Hawaii
1971
6860
52-75
10
Male
Agell
10
-75
Schober (7)
Maryland
1974
25 802
36-79
8
Male and
female
Age, sex,
period of
blood collection^
9
-73
Stahelin (S)
Basel
1971
3620
16-71
8
Male and
female
Age, sex
0
NA#
Wald (9)
London
1975
22 000
35-64
7
Male
Age, smoking
status, duration
of blood storage§
6
^ 0
*Approximate.
tAverage.
^Refers to original authors' analyses; all were nested case-control studies.
§Effectively matched on period of blood collection.
Illn the original analysis done by Nomura et al. (6), subjects were frequency matched by age; all other
studies were individually matched by age. See "Subjects and Methods" section for description of matching
procedure used in pooled analysis.
^Subjects were also matched according to whether they had been included in a private census of county
residents.
#Not applicable.
(6), controls had originally been frequen-
cy matched to cases. Stahelin et al. (8)
supplied data on their entire cohort before
selection of controls. To facilitate anal-
ysis of the combined data, the data from
Nomura et al. (6) and Stahelin et al. (8)
were reorganized so that each control in
these two studies was individually
matched to a case. The resulting matched
sets each had one case and one or more
controls. The matching factors were 5-
year-age category, gender, and 3-month
period since blood was drawn. Because
no match was available, five cases and 41
controls were excluded from the study by
Nomura et al. (6), and 2896 controls were
excluded from the study by Stahelin et al.
(8). Thus, data for 289 cases and 1267
controls matched by age, gender, and
period of blood collection were pooled
for the present analysis (Table 2).
The SAS statistical software package
was used to perform tabular analyses
(11). To evaluate the average difference
between the serum a-tocopherol concen-
trations for cases and their matched con-
trols, a general linear model was fitted to
the data. The dependent variable was
serum a-tocopherol concentration, and
the following parameters were estimated
for the independent variables: grand
(overall) mean, a fixed-effect term for
case-control status, and a random-effect
term representing set membership (12). A
likelihood ratio test was used to evaluate
the difference in fit between models, with
and without the term for case-control
status. Dose-response and multivariate
analyses were conducted with conditional
logistic regression models fitted with the
EGRET statistical software package (75).
The relationship of serum a-tocopherol
to risk of colorectal cancer was modeled
in two ways. 1) The quartiles of the a-to-
copherol distribution in controls were
determined for each study, and summary
odds ratios (ORs) (across all studies) ac-
cording to quartile were calculated. This
approach assumed that the OR for a given
quartile was constant across studies. 2)
The OR per 20 (imol/L increase in serum
a-tocopherol was calculated. Dietary sup-
plementation with 800 IU/d of a-to-
copherol results in an increase in serum
a-tocopherol of approximately 20 |J.mol/L
(14). This approach assumed that the rela-
tive risk per unit of a-tocopherol was
linear on the log scale. The study-specific
distributions of serum a-tocopherol levels
were skewed, long tail to the right. How-
Vol. 84, No. 6, March 18, 1992 REPORTS 431
Table 2. Serum a-tocopherol level for cases of colon cancer or rectal cancer and controls, by study*
Source of
data, first
author (ref. No.)
Knekt (5)
Nomura (6)
Schober (7)
Stahelin (5)
Wald (9)
Total*
No. of subjects
Colon cancer
Cases
21
78
72
18
17
206
Controls
37
188
143
536
34
938
Rectal cancer
Cases
37
30
0
5
11
83
Controls
71
72
0
165
21
329
a-Tocopherol,
Colon cancer
Cases
21.318.2
32.0+ 14.0
27.1±8.5
36.2 ± 10.2
25.4 ±11.0
29.0111.8
Controls
22.9 18.3
32.0+ 12.7
29.51 12.4
36.4110.4
25.319.0
30.01 11.7
umol/Lt
Rectal cancer
Cases
22.7 + 6.2
27.817.1
—
31.4 + 7.9
21.817.8
24.9 1 7.4
Controls
23.1 1 10.2
30.1110.8
—
36.8+ 11.6
24.0+14.4
25.9112.7
*Results based on data from five prospective case-control studies of colorectal cancer. Nos. of subjects in original papers of Stahelin et al. (S) and Nomura et al. (6)
differ from those included in present analysis. See "Subjects and Methods" section for explanation. The current study includes females from the Stahelin et al. cohort,
whereas the original report did not.
fValues = means 1 SD.
t-The overall mean of the values for serum a-tocopherol levels in controls was calculated as the arithmetic mean of values for cases plus the mean case-control dif-
ference estimated from the generalized linear model described in the "Subjects and Methods" section. The crude analysis indicated that for colon cancer the case
mean was significantly different from the control mean (/><.03). However, the difference after adjustment for serum cholesterol was not significant (P = .13). All
other case-control differences in the table were not statistically significant at the P = .05 level.
ever, analyses performed with log-trans-
formed serum a-tocopherol levels led to
the same conclusions as those conducted
with the untransformed values. Results
based on untransformed values were
presented to ease interpretation.
Results
The results of the individual studies
were relatively homogeneous. Within
each cohort, the concentration of a-
tocopherol tended to be similar among
cases and controls, although in a few in-
stances mean levels for cases were 1
|imol/L or more less than those for con-
trols (Table 2). The standard deviations
for the serum a-tocopherol concentra-
tions were large in each study; i.e., the
distributions overlapped substantially
among the cohorts. For colon cancer, the
overall average difference between case
and control serum a-tocopherol levels
was of borderline significance (P = .03);
for rectal cancer, the difference was not
significant (P = .17). When the average
difference was examined after adjustment
for serum cholesterol level, there were no
statistically significant differences be-
tween levels for cases and controls
(colon, P - . 13; rectum, P - AS).
The mean concentration for the highest
quartile of the serum a-tocopherol dis-
tribution in each study was approximately
25 |imol/L greater than that for the lowest
quartile (Table 3). The values for crude
OR according to quartile of serum a-to-
copherol concentration were generally
similar for cancer of the colon and for
cancer of the rectum (Table 4). For can-
cers of the colon and rectum combined,
the crude OR for the highest quartile
compared with the lowest was 0,6 (95%
confidence interval [CI] = 0.4-1.0). How-
ever, serum a-tocopherol and cholesterol
levels were correlated (Pearson r = .27, P
= .0001; calculated with log-transformed
a-tocopherol), and serum cholesterol
level was inversely associated with risk
of colorectal cancer. Thus, when the ORs
were adjusted for serum cholesterol level,
the association between serum a-tocoph-
erol concentration and colorectal cancer
risk was reduced (OR = 0.7; 95% CI =
0.4-1.1). Adjustment for cigarette smok-
ing status (current, past, or never) did not
affect the results.
To check for evidence of a threshold
effect for cancers of the colon and rectum
combined, a quadratic term was added to
the model, with a-tocopherol as a con-
tinuous variable. The additional term did
not improve the fit (P>.80). Using a
similar model, a test for heterogeneity in
effect across studies was performed, and
the results were consistent with homo-
Table 3. Ranges and means forquartiles of serum a-tocopherol concentration (in umol/L), by study*
First author (ref. No.)
Knekt (5)
Nomura (6)
Schober (7)
Stahelin (8)
Wald (9)
1
Range
9.3-<17.3
13.7-<24.0
14.2-<22.8
!5.6-<30.2
4.9-<17.4
Mean
14.0
20.7
19.7
26.4
12.8
2
Range
17.3-<21.7
24.0-<28.7
22.8-<26.8
30.2-<35.3
!7.4-<24.6
Quartile, u.mol/L
Mean
19.6
26.1
24.9
32.8
21.8
3
Range
21.7-<27.5
28.7-<35.1
26.8-<32.3
35.3-<4l.l
24.6-<29.3
Mean
24.2
31.4
29.5
38.2
26.8
4
Range
27.5-80.1
35.1-96.7
32.3-100.8
41.1-122.4
29.3-74.5
Mean
33.8
48.5
44.1
50.0
38.3
•Results based on data from five prospective case-control studies of colorectal cancer.
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geneity (P = .90). The association be-
tween serum a-tocopherol level and risk
of colorectal cancer was not appreciably
modified by cigarette smoking, age, or
gender. In the first 2.5 years of follow-up,
the relative risks of colorectal cancer in
subjects with serum a-tocopherol levels
in quartiles 2, 3, arid 4 were greater than 1
(Table 5). In later periods, the association
was almost uniformly inverse.
As noted above, serum cholesterol con-
centration was inversely associated with
risk of colorectal cancer. The OR per
mmol/L increase was 0.9 (95% CI = 0.8-
1.0). The OR for colorectal cancer among
those in the highest quartile of serum
cholesterol level relative to those in the
lowest was 0.6 (95% CI = 0.4-0.9). The
association did not vary with the number
of years between blood collection and
diagnosis. The ORs per mmol/L choles-
terol according to number of years were
the following: 0.9 for 0-2.4 years, 0.9 for
2.5-5.0 years, 0.9 for 5.0-7.5 years, and
0.8 for 7.5 years or more.
Discussion
The results suggest that serum a-to-
copherol concentration may be inversely
related to risk of colorectal cancer. The
laboratory procedures and the matching
procedures employed in the five studies
we used, together with the procedures
used in our current analysis, ensured that
differences between case and control
values, where present, were not due to
unequal length of specimen storage or to
variation over time in laboratory meas-
urement of serum a-tocopherol. How-
ever, it is unclear whether an association
exists between serum a-tocopherol level
and decreased risk of colorectal cancer
because, in our study, the association was
modest, the CIs were wide, and, overall,
the tests for trend in effect were not sig-
nificant.
Because colorectal cancer is common,
even a modest protective effect could
have important public health implica-
tions. Dietary intake of vitamin E is a
determinant of serum a-tocopherol level
(15). If an increase in daily vitamin E in-
take of 800 IU truly reduces the relative
risk of colorectal cancer by 20% or 30%
(within the CI of our estimate), this infor-
mation could be useful for preventive
health care.
One strength of the pooled analysis lies
in overcoming the problem of lack of
power in any individual study, especially
when subgroups are analyzed (16).
Another advantage is that uniform adjust-
ment for confounding factors is facili-
tated. If we had combined data from well-
conducted, randomized clinical trials, we
would have no serious concern about bias
in the summary findings (16). However,
because the results of the present analysis
reflect findings in observational studies,
biases, if any, in the component investi-
gations will be reflected in the summary.
The apparent association between a-
tocopherol level and decreased risk of
colorectal cancer may be due to uncon-
trolled confounding in our data from the
Table 4. ORs for risk of colorectal cancer according to quartile of serum a-tocopherol level and per 20-nmol/L increase in level, by cancer site*
Cancer site
Colon
Rectum
Colon and rectum
Type of OR
Crude
Adjusted!
Crude
Adjusted!
Crude
Adjusted!
1
1.0
1.0
1.0
1.0
1.0
1.0
2
0.9(0.5-1.4)
0.9(0.6-1.5)
0.8(0.4-1.8)
0.8(0.4-1.8)
0.9(0.6-1.3)
0.9(0.6-1.3)
Ouartile
3
0.7(0.4-1.2)
0.8(0.5-1.3)
1.0(0.4-2.2)
1.0(0.4-2.2)
0.8(0.5-1.2)
0.8(0.5-1.3)
4
0.6(0.4-1.1)
0.7(0.4-1.3)
0.6(0.2-1.6)
0.6(0.2-1.5)
0.6(0.4-1.0)
0.7(0.4-1.1)
P value for trend
across quartiles
.06
.26
.32
.41
.03
.15
Per 20 |imol/L increase
0.82(0.61-1.11)
0.90(0.63-1.27)
0.59(0.30-1.16)
0.59(0.28-1.20)
0.77(0.58-1.02)
0.82(0.60-1.11)
P value
for increase
.21
.55
.13
.15
.07
.20
•Results based on pooled data from five prospective case-control studies of colorectal cancer. Estimates were from conditional logistic regression models. Values
in parentheses = 95% CIs. Subjects with the lowest serum a-tocopherol concentrations are in quartile 1.
tAdjusted for serum cholesterol level.
Table 5. ORs for risk of colorectal cancer according to quartile for serum a-tocopherol level, by No. of years between blood collection and diagnosis*
No. of years
<2.5
2.5-<5.0
5.0-<7.5
>7.5
Type of OR
Crude
Adjustedt
Crude
Adjustedt
Crude
Adjustedt
Crude
Adjustedt
1
.0
.0
.0
.0
.0
.0
.0
.0
2
2.7(1.0-7.3)
2.9(1.0-8.1)
0.5(0.2-1.0)
0.4(0.2-1.0)
0.9(0.4-1.9)
0.9 (0.4-2.0)
0.5(0.2-1.3)
0.6(0.2-1.5)
Quartilet
3
1.5(0.6-4.3)
1.7(0.6-5.2)
0.8(0.4-1.6)
0.7(0.3-1.6)
0.8(0.4-1.8)
0.8(0.3-1.8)
0.6(0.2-1.4)
0.7 (0.3-2.0)
4
1.2(0.4-3.6)
1.6(0.5-5.4)
0.6(0.3-1.2)
0.6(0.3-1.3)
0.3(0.1-0.8)
0.3(0.1-0.8)
0.8(0.3-1.9)
1.2(0.4-3.3)
P value for trend
across quartiles
.75
.90
.31
.44
.02
.03
.64
.70
No. of cases
66
89
77
55
No. of controls
180
344
219
524
•Estimates were from conditional logistic regression models.
jSubjects with the lowest serum a-tocopherol concentrations are in quartile 1. Study-specific quartiles are specified in Table 3.
tAdjusted for serum cholesterol level.
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five studies we used. In the United States,
fats, oils, and vegetables are the major
sources of dietary vitamin E (77); an ob-
served protective association could be
due to constituents of these foods other
than.vitamin E or to behaviors associated
with eating such foods.
Serum a-tocopherol level is deter-
mined, in part, by serum lipoprotein con-
centration (18). Serum cholesterol level
can be reduced in persons with cancer
that is not yet clinically detectable, in-
cluding colorectal cancer (19-22). The ef-
fect is usually greatest within 2 years
before diagnosis, although Tomberg et al.
(21) found that, for all cancers combined,
persons with a low baseline cholesterol
level still had a slightly greater risk of
cancer even 10 years later. In the current
data, the length of time after blood collec-
tion did not modify the relationship be-
tween cholesterol level and cancer risk,
even though it did in one of the con-
stituent studies (9). Although the precise
reasons for the inverse relationship be-
tween serum cholesterol level and risk of
colorectal cancer are not entirely clear,
the association of serum a-tocopherol
concentration with risk of colorectal can-
cer was adjusted for serum cholesterol
concentration to avoid confounding.
The serum specimens collected by
Stahelin et al. (8) were analyzed immedi-
ately after the blood was drawn; vitamin
E levels among those subjects were the
highest in the five cohorts. The specimens
collected by Knekt et al. (5) were stored
for a longer period than in any of the
other studies, and vitamin E levels among
the subjects were the lowest in the five
cohorts. The rate of decay of serum a-to-
copherol concentration in sera frozen at
-40 °C was observed by Wald et al. (9) to
be 1.2 |omol L"'y"'. If one assumes that
the decay of a-tocopherol in our speci-
mens was proportional to storage temper-
ature and length of storage, it is possible
to estimate, based on Wald's decay rate
at -40 °C, the mean serum a-tocopherol
level in each cohort at the time the blood
was drawn. Such estimates suggest that
the mean a-tocopherol levels in the
specimens from the cohorts were more
similar at the time the blood was drawn
than in the stored specimens. However,
Gey et al. (23) found that the a-tocoph-
erol concentration in freshly analyzed
sera from subjects from Finland was re-
markably similar to the levels Knekt et al.
(5) observed in sera after storage. Thus,
the differences in serum a-tocopherol
levels observed among cohorts may have
been largely due to true population dif-
ferences rather than to storage conditions.
If the rates of degradation of a-tocoph-
erol were equivalent for the corres-
ponding cases and controls within case-
control sets, degradation would have had
no effect on the observed ORs. Any
departure from equality of case-control
degradation rates would have resulted in
misclassification of relative levels and,
thus, less precise and possibly biased re-
sults. For example, serum cholesterol
and, by inference, serum lipoprotein
levels were associated with serum a-to-
copherol levels. If lipoprotein concentra-
tion in the stored specimens was asso-
ciated with rate of loss of a-tocopherol,
the results might be biased toward the
null. Although the observed association
might have been more precise, and pos-
sibly stronger, in the absence of degrada-
tion, the fact that the findings did not vary
markedly across studies suggests that our
findings were not seriously distorted by
differences in specimen preservation.
Although vitamin E inhibits mutagen-
esis and cell transformation (/), its anti-
carcinogenic effects, if any, may be
through other mechanisms. For example,
because vitamin E is excreted in bile (24),
it might influence large-bowel carcino-
genesis in the lumen of the gut. Dion et
al. (25) showed that dietary supplementa-
tion with vitamins E and C reduces the
mutagenicity of feces. Nonetheless, ani-
mal data regarding large-bowel cancer
and vitamin E are contradictory (7).
Results of experimental studies of polyp
recurrence in humans are compatible with
a modest inhibitory effect of vitamin E
(26,27), but the effects have not been
statistically significant and could be due
to concurrently administered vitamin C.
In the present analysis, the evidence sup-
porting a causal relationship between vi-
tamin E level and colorectal cancer is
equivocal. If vitamin E truly has a subtle
protective effect against colorectal can-
cer, one might expect results like that ob-
served—a monotonic modest decrease in
risk with increasing quartile of serum a-
tocopherol concentration and little statis-
tical precision.
The evidence for a protective effect of
vitamin E is weak—certainly not strong
enough to justify an intervention study
powerful enough to detect an effect, if in-
deed one exists. In the meantime, larger
observational studies with control for
confounding by other dietary factors will
be needed to determine whether vitamin
E has a modest but potentially important
protective effect against colorectal can-
cer.
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Phase II Study: Treatment of
Non-Hodgkin's Lymphoma
With an Oral Antitumor
Derivative of
Bis(2,6-dioxopiperazine)
Ryuzo Ohno* Kazumasa
Yamada, Masami Hirano, Shigeru
Shirakawa, Masao Tanaka,
Takashi Oguri, Yoshihisa Kodera,
Yasuharu Mitomo, Yasushi Ikeda,
Shozo Yokomaku, Osamu Kamiya,
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Blood Cancer Study Group
Background: Although razoxane (ICRF-
159), a derivative of bis(2,6-dioxopiper-
azine), has shown significant antitumor
activity in several murine tumors, in-
adequate bioavailability has limited its
clinical efficacy. Sobuzoxane (MST-16),
another derivative of bis(2,6-dioxopi-
perazine), has shown activity against a
broad spectrum of murine tumors and
human tumor xenografts in nude mice
and a lack of cross-resistance to vin-
cristine, doxorubicin, cyclophospha-
mide, fluorouracil, etoposide, and
mitomycin C. These findings suggest
that MST-16 has a mode of cytocidal
activity different from that of other
antitumor agents. Purpose: The present
late phase II study was conducted to
evaluate the clinical efficacy and
toxicity of MST-16 in non-Hodgkin's
lymphoma (NHL). Methods: As part of
a multi-institutional cooperative study,
we conducted a study of MST-16 in 27
patients with NHL who were assessable
for drug efficacy and toxicity. MST-16,
a bis(2,6-dioxopiperazine) analogue
and an inhibitor of topoisomerase II,
was administered orally at a dose of
1600 mg/m2 a day for 5-7 days at inter-
vals of 2-3 weeks. Results: Response
consisted of one complete remission
and seven partial remissions in 27 as-
sessable patients. Response was
achieved at a median of 13 days (range,
9-62 days) after initiation of therapy
and lasted a median of 46 days (range,
29-155 days). Major toxic effects were
leukopenia in 70% of the patients,
thrombocytopenia in 44%, and gastro-
intestinal disorders in 37%. Conclu-
sions: MST-16 was shown to be ef-
fective in NHL and deserves further
clinical trial, since the drug shows little
cross-resistance to available antitumor
drugs. Implications: Phase II clinical
studies of MST-16 in treatment of
breast cancer, gastric cancer, and adult
T-cell leukemia and lymphoma are also
being conducted in Japan. Future trials
of combination chemotherapy using
MST-16 with other antitumor drugs
are warranted in view of the additive
effects observed in studies of MOLT-3
cells and studies of L1210 leukemia in
mice. [J Natl Cancer Inst 84:435-438,
1992]
4,4'-(l,2-Ethanediyl)bis(l-isobutoxy-
carbonyloxymethyl-2,6-piperazinedione)
(MST-16, sobuzoxane) (Fig. 1) is an anti-
tumor agent that can be administered
orally. It is a derivative of bis(2,6-dioxo-
piperazine) (1). Although ICRF-159
(razoxane), another derivative of bis-
(2,6-dioxopiperazine), showed signif-
icant antitumor activity in several
murine tumors, its inadequate bio-
availability has limited its clinical ef-
ficacy (2-5). MST-16 has been selected
from a number of synthetic derivatives
of bis(2,6-dioxopiperazine) as the most
promising compound for clinical use
(6,7). It has shown a broad spectrum of
activity against murine tumors includ-
ing L1210 leukemia, P388 leukemia,
B16 melanoma, Colon26 carcinoma,
and Lewis lung carcinoma, as well as
against human tumor xenografts such as
MX-1 breast carcinoma, CO-4 colon
carcinoma, and LX-1 lung carcinoma in
nude mice. Results of these studies
demonstrate a higher therapeutic ratio
than that for ICRF-159 (7). MST-16
demonstrated no cross-resistance to vin-
cristine, doxorubicin, cyclophosphamide,
fluorouracil, etoposide, or mitomycin-C,
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